The Committee for Medicinal Products for Human Use (CHMP) decided that Lyrica’ s benefits are greater than its risks for the treatment of peripheral and central neuropathic pain in adults, as therapy in adults with partial seizures with or without secondary generalisation, and for the treatment of Generalised Anxiety Disorder in adults.